Andrological aspects of the effects of gonadotropinreleasing hormone agonists in experiment and clinic

A literature search was made to study works devoted to the results of gonadotropinreleasing hormone agonists (GnRHa) using in  men in  clinical settings and  male animals in experiments. Almost all researchers claim that GnRHa suppress testicular function. But there is no clear opinion regarding the mechanisms of this effect: some scientists believe that a direct effect of drugs on testicular cells is possible, others believe that such an effect is indirect through other hormones, including pituitary ones. Most published articles provide evidence of a decrease in mass with atrophy of prostate and seminal vesicle tissue after the use of GnRHa. The effect is similar to surgical castration, but appears somewhat later and sometimes less pronounced, since testosterone synthesis is not completely suppressed. In the complex therapeutic treatment of prostate cancer, drugs of this group provide comparable effectiveness to orchiectomy or high doses of estrogens, while a lower frequency of side effects has  been recorded. GnRH has an  antiproliferative effect on  the  cells of  prostate carcinomas, but at  the  same time there is  an  opinion that GnRHa do  not inhibit the  proliferation of  prostate cancer cells, and that direct suppression of  mitotic activity is unlikely to be the main mechanism of the antitumor effect of such drugs. When studying the data on the protective effect of GnRH drugs on the cells and tissues of the genital organs during chemotherapy and radiation, attention is drawn to the obvious inconsistency of publications: from a good effect with a rapid restoration of functional activity, to weak or even completely absent positive dynamics. In any case, the inconsistency of publications on each aspect of the effects of GnRH indicates that they have been poorly studied, and the advisability of further continuing not  only applied research, but also fundamental research, due to  its possible high prospects.

1. Meccariello R, Fasano S, Pierantoni R. Kisspeptins, new local modulators of male reproduction: A comparative overview. Gen Comp Endocrinol. 2020; 299: 113618. doi: 10.1016/j.ygcen.2020.113618

2. ZhaoW, AdjeiM, ZhangZ, YuanZ, CisangZ, SongT. The role of GnRH in Tibetan male sheep and goat reproduction. Reprod Domest Anim. 2023; 58: 1179-1187. doi: 10.1111/rda.14432

3. EvansMC, AndersonGM. The role of RFRP neurons in the allostatic control of reproductive function. Int J Mol Sci. 2023; 24: 15851. doi: 10.3390/ijms242115851

4. Verrotti A, Penta L, Zenzeri L, Lucchetti L, Giovenali P, De Feo P. True precocious puberty following treatment of a Leydig cell tumor: Two case reports and literature review. Front Pediatr. 2015; 3: 93. doi: 10.3389/fped.2015.00093

5. SchagenSE, Cohen-KettenisPT, Delemarre-vandeWaalHA, Hannema SE. Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016; 13: 1125-1132. doi: 10.1016/j.jsxm.2016.05.004

6. Giannakopoulos A, Fryssira H, Tzetis M, Xaidara A, KanakaGantenbein C. Central precocious puberty in a boy with 22q13 deletion syndrome and NOTCH-1 gene duplication. J Pediatr Endocrinol Metab. 2016; 29: 1307-1311. doi: 10.1515/jpem-2015-0484

7. Pereira SA, Oliveira FCB, Naulé L, Royer C, Neves FAR, Abreu AP, et al. Mouse testicular Mkrn3 expression is primarily interstitial, increases peripubertally, and is responsive to LH/hCG. Endocrinology. 2023; 164: bqad123. doi: 10.1210/endocr/bqad123

8. Labrie F. Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology. J Steroid Biochem Mol Biol. 2015; 145: 144-156. doi: 10.1016/j.jsbmb.2014.05.012

9. HoriJI, Koga D, Kakizaki H, Watanabe T. Differential effects of depot formulations of GnRH agonist leuprorelin and antagonist degarelix on the seminiferous epithelium of the rat testis. Biomed Res. 2018; 39: 197-214. doi: 10.2220/biomedres.39.197

10. Demir A, Büyükgebiz A, Aydin A, Hero M. Quantification of overnight urinary gonadotropin excretion predicts imminent puberty in girls: A semi-longitudinal study. Hormones (Athens). 2023; 23(1): 141-145. doi: 10.1007/s42000-023-00499-7

11. Moradi SV, Varamini P, Toth I. Evaluation of the biological properties and the enzymatic stability of glycosylated luteinizing hormone-releasing hormone analogs. AAPS J. 2015; 17: 1135-1143. doi: 10.1208/s12248-015-9769-x

12. Jyrkäs J, Lassila T, Tolonen A. Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds. J Pharm Biomed Anal. 2023; 225: 115219. doi: 10.1016/j.jpba.2022.115219

13. Birrell JR, Schulman ML, Botha AE, Ganswindt A, Fosgate GT, Bertschinger HJ. Vaccination against GnRH as a prelude to surgical castration of horses. Equine Vet J. 2021; 53: 1141-1149. doi: 10.1111/evj.13411

14. Rosenfield DA, Nichi M, Losano JDA, Kawai G, Leite RF, Acosta AJ, et al. Field-testing a single-dose immunocontraceptive in free-ranging male capybara (Hydrochoerus hydrochaeris): Evaluation of effects on reproductive physiology, secondary sexual characteristics, and agonistic behavior. Anim Reprod Sci. 2019; 209: 106148. doi: 10.1016/j.anireprosci.2019.106148

15. Giriboni J, Lacuesta L, Santiago-Moreno J, Ungerfeld R. Chronic use of a GnRH agonist (deslorelin) or immunization against GnRH: Effects on testicular function and sperm quality of bucks. Domest Anim Endocrinol. 2020; 71: 106395. doi: 10.1016/j.domaniend.2019.106395

16. Gautier C, Aurich J, Kaps M, Okada CTC, Wagner LH, Melchert M, et al. Re-stimulation of testicular function in GnRH-vaccinated stallions by daily GnRH agonist treatment. Theriogenology. 2022; 194: 27-34. doi: 10.1016/j.theriogenology.2022.09.011

17. Zvereva I, Dudko G, Dikunets M. Determination of GnRH and its synthetic analogues’ abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers. Drug Test Anal. 2018; 10: 711-722. doi: 10.1002/dta.2256

18. Prestel L, Joerling J, Failing K, WagnerH, Wehrend A. Suppression of reproductive function in juvenile rams by a slow-release gonadotropin-releasing hormone implant. Open Vet J. 2022; 12: 171-181. doi: 10.5455/OVJ.2022.v12.i2.3

19. Yutong M, Liang Y, Chunjie S, Xiaolin G, Xiaoyan G, Lin D, et al. Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats. Front Pharmacol. 2023; 14: 1125255. doi: 10.3389/fphar.2023.1125255

20. Meccariello R, Fasano S, Pierantoni R. Kisspeptins, new local modulators of male reproduction: A comparative overview. Gen Comp Endocrinol. 2020; 299: 113618. doi: 10.1016/j.ygcen.2020.113618

21. Huhtaniemi IT, Clayton RN, Catt KJ. Gonadotropinreleasing hormone agonist analog-induced steroidogenic lesion in the neonatal rat testis: Evidence for direct gonadal action. Endocrinology. 1984; 115: 233-238. doi: 10.1210/endo-115-1-233

22. Hadziselimovic F, Verkauskas G, Vincel B, Stadler MB. Testicular expression of long non-coding RNAs is affected by curative GnRHa treatment of cryptorchidism. Basic Clin Androl. 2019; 29: 18. doi: 10.1186/s12610-019-0097-3

23. Cheng PJ, Pastuszak AW, Myers JB, Goodwin IA, Hotaling JM. Fertility concerns of the transgender patient. Transl Androl Urol. 2019; 8: 209-218. doi: 10.21037/tau.2019.05.09

24. Adeleye AJ, Stark BA, Jalalian L, Mok-Lin E, Smith JF. Evidence of spermatogenesis in the presence of hypothalamic suppression and low testosterone in an adolescent transgender female: A case report. Transgend Health. 2023; 8: 104-107. doi: 10.1089/trgh.2021.0034

25. Peirouvi T, Salami S. GnRH agonist induces apoptosis in seminiferous tubules of immature rats: Direct gonadal action. Andrologia. 2010; 42: 231-235. doi: 10.1111/j.1439-0272.2009.00982.x

26. Eşki F, Çetin N, Uslu S, Uslu BA, Şendağ S, Yörük M, et al. Effects of long-term release GnRH agonist “deslorelin” on testicular HSP expression, accessory sex glands and testicular functions in adult male rats. Theriogenology. 2013; 134: 104-111. doi: 10.1016/j.theriogenology.2019.05.016

27. Goblet CC, Moresco A, Garner MM, Agnew DW, NewellFugateAE. Retrospective characterization of reproductive tract lesions in relation to age, parity, and contraception in captive suidae and tayassuidae. Theriogenology. 2019; 127: 137-144. doi: 10.1016/j.theriogenology.2019.01.012

28. Driancourt MA, Briggs JR. Gonadotropin-releasing hormone (GnRH) agonist implants for male dog fertility suppression: A review of mode of action, efficacy, safety, and uses. Front Vet Sci. 2020; 7: 483. doi: 10.3389/fvets.2020.00483

29. StempelS, Goericke-PeschS. GnRH-Agonisten in der Kleintierpraxis – Was wissen wir 13 Jahre nach der EU-Zulassung? [GnRH agonist implants in small animal practice – What do we know 13 years following EU registration?]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2020; 48: 420-432. (In German). doi: 10.1055/a-1274-9268

30. Balogh O, Somoskői B, Kollár E, Kowalewski MP, Gram A, ReichlerIM, et al. Anti-Müllerian hormone, testosterone, and insulin-like peptide 3 as biomarkers of Sertoli and Leydig cell function during deslorelin-induced testicular downregulation in the dog. Theriogenology. 2021; 175: 100-110. doi: 10.1016/j.theriogenology.2021.08.017

31. Faya M, Marchetti C, Priotto M, Grisolía M, D’Francisco F, GobelloC. Postponement of canine puberty by neonatal administration of a long term release GnRH superagonist. Theriogenology. 2018; 118: 190-195. doi: 10.1016/j.theriogenology.2018.05.043

32. VasetskaA, KörberH, PilgramC, SchulerG, AslanS, SaralG, et al. The use of a 4.7 mg deslorelin slow release implant in male dogs in the field. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2023; 51: 231-241. doi: 10.1055/a-2142-4194

33. Stempel S, Körber H, Reifarth L, Schuler G, GoerickePeschS. What happens in male dogs after treatment with a 4.7 mg deslorelin implant? II. Recovery of testicular function after implant removal. Animals (Basel). 2022; 12: 2545. doi: 10.3390/ani12192545

34. Tran HD, Carroll KE, Mackiewicz AL, Ardeshir A, Stockinger D, de Lucena T, et al. Effects of deslorelin on testosterone secretion and testicular volume in male rhesus macaques (Macaca mulatta). J Am Assoc Lab Anim Sci Epub. 2023; 62(6): 525-530. doi: 10.30802/AALAS-JAALAS-22-000116

35. Mehl NS, Khalid M, Srisuwatanasagul S, SwangchanUthai T, SirivaidyapongS. GnRH-agonist implantation of prepubertal male cats affects their reproductive performance and testicular LH receptor and FSH receptor expression. Theriogenology. 2016; 85: 841-848. doi: 10.1016/j.theriogenology.2015.10.031

36. Romagnoli S, Baldan A, Ferro S, Righetti C, Scenna L, Gabai G, et al. Length of efficacy and effect of implant location in adult tom cats treated with a 9.4 mg deslorelin subcutaneous implant. J Feline Med Surg. 2019; 21: 507-519. doi: 10.1177/1098612X18788157

37. Novotny R, Vitasek R, Bartoskova A, Cizek P, Prinosilova P, Novakova K. Azoospermia with variable testicular histology after 7 months of treatment with a deslorelin implant in toms. Theriogenology. 2015; 83: 1188-1193. doi: 10.1016/j.theriogenology.2014.12.026

38. Nuñez Favre R, García MF, García Mitacek MC, Rearte R, Fontaine C, de la Sota RL, et al. Reestablishment of sperm quality after long-term deslorelin suppression in tomcats. Anim Reprod Sci. 2018; 195: 302-308. doi: 10.1016/j.anireprosci.2018.06.008

39. Bonacina E, Negri G, Mattiello S, Gabai G, Groppetti D. Deslorelin subcutaneous implants in Oryx dammah males for reproductive control. Theriogenology. 2020; 149: 72-78. doi: 10.1016/j.theriogenology.2020.03.018

40. Gautier C, Schmidt K, Aurich J, Aurich C. Effects of implants containing the GnRH agonist deslorelin on testosterone release and semen characteristics in Shetland stallions. Anim Reprod Sci. 2018; 195: 230-241. doi: 10.1016/j.anireprosci.2018.05.027

41. Goericke-Pesch S, Groeger G, Wehrend A. The effects of a slow release GnRH agonist implant on male rabbits. Anim Reprod Sci. 2015; 152: 83-89. doi: 10.1016/j.anireprosci.2014.11.002

42. Fakriadis I, Zanatta EM, Fleck RPDS, Sena Mateo DL, PapadakiM, MylonasCC. Endocrine regulation of long-term enhancement of spermiation in meagre (Argyrosomus regius) with GnRHa controlled-delivery systems. Gen Comp Endocrinol. 2020; 297: 113549. doi: 10.1016/j.ygcen.2020.113549

43. Baş F, Abalı ZY, ToksoyG, Poyrazoğlu Ş, Bundak R, Güleç Ç, et al. Precocious or early puberty in patients with combined pituitary hormone deficiency due to POU1F1 gene mutation: Case report and review of possible mechanisms. Hormones (Athens). 2018; 17: 581-588. doi: 10.1007/s42000-018-0079-4

44. Sansone A, Schubert M, Tüttelmann F, Krallmann C, Zitzmann M, Kliesch S, et al. Pituitary response to GnRH stimulation tests in different FSHB-211 G/T genotypes. Hum Reprod. 2021; 36: 1376-1382. doi: 10.1093/humrep/deab033

45. Trachtenberg J. The effect of the chronic administration of a potent luteinizing hormone releasing hormone analog on the rat prostate. J Urol. 1982; 128: 1097-1100.

46. Lamberts SW, Uitterlinden P, de Jong FH. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropinreleasing hormone analogue. Cancer Res. 1988; 48(21): 6063-6068.

47. Kuber W, Treu T, Kratzik C, Girsch E, Zeillinger R, Spona J. Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma – Clinical, endocrinological and experimental studies. Wien Klin Wochenschr. 1990; 102: 640-647.

48. Moguilewsky M, Tournemine C. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat. Am J Clin Oncol. 1988; 11(Suppl 2): S148-S151.

49. Séguin C, Cusan L, Bélanger A, Kelly PA, Labrie F, Raynaud JP. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol Cell Endocrinol. 1981; 21: 37-41.

50. Labrie F, DupontA, BelangerA, Lefebvre FA, CusanL, Monfette G, et al. New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem. 1983; 19: 999-1007.

51. Maezawa H, Komatsu H, Kawaoi A, Ueno A. Potentiating effect of buserelin acetate, an LHRH agonist, on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J Urol. 1997; 4: 411-416.

52. Khadivi B, Peirouvi T, Javanmardi MZ, Rasmi Y. Shortterm buserelin administration induces apoptosis and morphological changes in adult rat testes. Acta Cir Bras. 2017; 32: 140-147. doi: 10.1590/s0102-865020170206

53. van SteenbruggeGJ, Romijn JC, de JongFH, Schröder FH. Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630). Urol Res. 1984; 12: 175-178.

54. Dubé JY, FrenetteG, Tremblay RR, Tremblay Y, BélangerA. Involution of spontaneous benign prostatic hyperplasia in the dog under the influence of chronic treatment with a LHRH agonist. Prostate. 1984; 5: 417-423.

55. DamberJE, BerghA, WidmarkA. Effect of an LHRH-agonist on testicular microcirculation in hypophysectomized rats. Int J Androl. 1987; 10: 785-791.

56. Bergh A, Damber JE. Treatment with an LHRH agonist or hCG increases interstitial fluid volume and permeability to Evans blue in the mouse testis. Int J Androl. 1988; 11: 449-456.

57. UngerfeldR, FilaD. Testicular fluid content evaluated by ultrasound image computer-assisted analysis increases with smalldose multiple GnRH injections in rams. Reprod Domest Anim. 2011; 46: 720-723. doi: 10.1111/j.1439-0531.2010.01735.x

58. El-Shalofy AS, Hedia MG. Effects of buserelin administration on testicular blood flow and plasma concentrations of testosterone and estradiol-17β in rams. Domest Anim Endocrinol. 2021; 77: 106646. doi: 10.1016/j.domaniend.2021.106646

59. Vencato J, Cestaro L, Vazzana I, Carrer G, Carlo E, Dara S, Stelletta C. Integrated evaluation of scrotal temperature and testosteronemia after GnRH administration in young bulls with low semen production. Reprod Domest Anim. 2014; 49: 481-486. doi: 10.1111/rda.12315

60. Roelfsema F, Liu PY, Takahashi PY, Yang RJ, Veldhuis JD. Dynamic interactions between LH and testosterone in healthy community-dwelling men: Impact of age and body composition. J Clin Endocrinol Metab. 2020; 105: e628-e641. doi: 10.1210/clinem/dgz246

61. ChungJY, BrownS, ChenH, LiuJ, PapadopoulosV, ZirkinB. Effects of pharmacologically induced Leydig cell testosterone production on intratesticular testosterone and spermatogenesis. Biol Reprod. 2020; 102: 489-498. doi: 10.1093/biolre/ioz174

62. Taniguchi H, Katano T, Nishida K, Kinoshita H, Matsuda T, ItoS. Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model. Andrology. 2016; 4: 964-971. doi: 10.1111/andr.12213

63. Spruijt A, Kooistra H, Oei C, Vinke C, Schaefers-Okkens A, DeGierJ. The function of the pituitary-testicular axis in dogs prior to and following surgical or chemical castration with the GnRHagonist deslorelin. Reprod Domest Anim. 2023; 58: 97-108. doi: 10.1111/rda.14266

64. Gültiken N, Aslan S, Ay SS, Gülbahar MY, Thuróczy J, Koldaş E, et al. Effect of deslorelin on testicular function, serum dihydrotestosterone and oestradiol concentrations during and after suppression of sexual activity in tom cats. J Feline Med Surg. 2017; 19: 123-131. doi: 10.1177/1098612X15615381

65. Enomoto M, Mori T, Park MK. GnRH agonist Buserelin affects colony-forming efficiency of HHUA and Jurkat cells. Biochem Biophys Res Commun. 2001; 289: 1180-1187. doi: 10.1006/bbrc.2001.6131

66. OduwoleOO, PoliandriA, OkoloA, RawsonP, Doroszko M, Chrusciel M, et al. Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts. FASEB J. 2021; 35: e21464. doi: 10.1096/fj.202002168RR

67. Beacock CJ, Buck AC, Zwinck R, Peeling WB, Rees RW, Turkes A, et al. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630. Br J Urol. 1987; 59: 436-442. doi: 10.1111/j.1464-410x.1987.tb04842.x

68. SandowJ. Clinical applications of LHRH and its analogues. Clin Endocrinol (Oxf ). 1983; 18: 571-592. doi: 10.1111/j.1365-2265.1983.tb00595.x

69. Geldof AA, de Voogt HJ, Rao BR. Renewal timing of longacting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H). Prostate. 1987; 11: 281-290. doi: 10.1002/pros.2990110308

70. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, MottaM. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res. 1994; 54: 4091-4095.

71. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, et al. New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med. 1982; 5: 267-275.

72. Rousset-Jablonski C, Chevillon F, Dhedin N, Poirot C. Préservation de la fertilité chez les adolescents et jeunes adultes traités pour cancer [Fertility preservation in adolescents and young adults with cancer]. Bull Cancer. 2016; 103: 1019-1034. (In French). doi: 10.1016/j.bulcan.2016.10.008

73. GulinoG, DistanteA, AkhundovA, BassiPF. Male infertility and urological tumors: Pathogenesis and therapeutical implications. Urologia. 2023; 90: 622-630. doi: 10.1177/03915603221146147

74. Zachau L, Zeckey C, Schlue J, SanderJ, Meyer-Heithuis C, Winkler M, et al. Haematogenous abdominal wall metastasis of differentiated, alpha-fetoprotein-negative hepatocellular carcinoma after previous antiandrogen therapy within a site of lipoma manifestation since childhood. World J Surg Oncol. 2012; 10: 98. doi: 10.1186/1477-7819-10-98

75. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: A metaanalysis of randomized controlled trials. Eur Urol. 2021; 79: 44-53. doi: 10.1016/j.eururo.2020.06.002

76. Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, et al. The efficacy and safety of Relugolix compared with Degarelix in advanced prostate cancer patients: A network meta-analysis of randomized trials. Eur Urol Oncol. 2022; 5: 138-145. doi: 10.1016/j.euo.2021.07.002